- Home
- EAF vs ENLV Comparison
EAF vs ENLV Comparison
Compare EAF & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EAF | ENLV |
|---|---|---|
| Founded | 1886 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.6M | 149.0M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | EAF | ENLV |
|---|---|---|
| Price | $6.85 | $1.47 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 2 |
| Target Price | $11.75 | ★ $20.00 |
| AVG Volume (30 Days) | 275.8K | ★ 310.9K |
| Earning Date | 05-01-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $504,134,000.00 | N/A |
| Revenue This Year | $4.25 | N/A |
| Revenue Next Year | $12.49 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.92 | $0.43 |
| 52 Week High | $20.32 | $7.64 |
Technical Indicators
Market Signals| Indicator | EAF | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 36.93 |
| Support Level | $6.16 | $0.70 |
| Resistance Level | $8.21 | $1.81 |
| Average True Range (ATR) | 0.43 | 0.23 |
| MACD | -0.11 | -0.08 |
| Stochastic Oscillator | 15.88 | 10.34 |
Price Performance
Historical ComparisonAbout EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products used as raw material in the production of graphite electrodes.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.